SCHEMBL118273

SCHEMBL118273

COC(=O)c1ccc(S(=O)(=O)Nc2ccc(C(F)(F)F)cc2Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.51
MCL1 Q07820 1/20 0.51
CYP2C9 P11712 3/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
LMNA P02545 1/20 0.50
CCR9 P51686 1/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
TSHR P16473 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
AVPR2 P30518 1/20 0.47
GPR27 Q9NS67 1/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
ACLY P53396 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7572555 0.84 CYP2C9 (0.60) KDM1ACYP2C9KDM4EALDH1A1LMNA
SCHEMBL10826418 0.82 KDM1A (0.62) KDM1AMCL1CYP2C9LMNACCR9
SCHEMBL119695 0.81 MEN1 (0.71) KDM4EALDH1A1LMNANPSR1SMN1; SMN2
SCHEMBL10840713 0.79 MCL1 (0.57) KDM1AMCL1ALDH1A1LMNATSHR
SCHEMBL5300106 0.79 KDM1A (0.71) KDM1AMCL1KDM4EALDH1A1CCR9
SCHEMBL23141168 0.77 KDM1A (0.61) KDM1ACCR9AVPR2GPR27ACLY
SCHEMBL3528690 0.77 KDM1A (0.61) KDM1ACYP2C9LMNACCR9NPSR1
SCHEMBL7452624 0.77 RXFP1 (0.54) MCL1KDM4EALDH1A1LMNATSHR
SCHEMBL1138776 0.76 MAPT (0.50) KDM1ACYP2C9KDM4EALDH1A1LMNA
SCHEMBL7567314 0.76 NPSR1 (0.59) CYP2C9ALDH1A1LMNACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 KDM1A 1281/4885MCL1 3367/4885CYP2C9 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.